DDrare: Database of Drug Development for Rare Diseases

95. 自己免疫性肝炎
［臨床試験数：44，薬物数：57（DrugBank：26），標的遺伝子数：18，標的パスウェイ数：108］

Searched query = "Autoimmune hepatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AZATHIOPRINE; Abatacept; Anti-BAFFR antibody; Anti-BAFFr antibody; Azathioprine; Budesonide; Calcium; Cannabidiol; Chloroquine; Chloroquine diphosphate; Chloroquine diphosphate 250mg; Cyclosporin; Cyclosporin A; Cyclosporine; Cyclosporine-A; Denosumab; EFALIZUMAB; Efalizumab; Erythropoietin; Gold; High protein high fiber diet; INTERLEUKIN 2; Ianalumab; Inflectra (Infliximab); Infliximab; Interleukin 2; JKB-122; JKB-122 in capsule or tablet form; LCP-Tacro (tacrolimus); MYCOPHENOLATE MOFETIL; Metronidazole; Minodronic acid; Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofeti; Mycophenolate mofetil; Orbcel-C; Orencia® (Abatacept); PREDNISOLONE SODIUM SUCCINATE; Prednisolone; Prednisone; Preimplantation factor; Raptiva; Raptiva 100 mg/ml powder and solvent for solution for injection; Regulatory T cells; Risedronic acid; SPIF; Synthetic PreImplantation Factor; Tacrolimus; Treatment with azathioprin; Treatment with mycophenolat mofetil; Ursodeoxycholic Acid; Ursodeoxycholic acid; Ursodeoxycholic acid combination of immunosuppressive agents; VAY736; Vitamin D; Zoledronic acid

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02936596 (ClinicalTrials.gov)	December 2016	15/10/2016	Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome	Biochemical Response of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Induced by Ursodeoxycholic Acid Only or Combination Therapy of Immunosuppressive Agents	Hepatitis, Autoimmune;Cholangitis;Liver Cirrhosis, Biliary;Cholestasis	Drug: Ursodeoxycholic acid combination of immunosuppressive agents;Drug: Ursodeoxycholic Acid	Xiaoli Fan	NULL	Recruiting	18 Years	75 Years	All	53	N/A	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02936596
(ClinicalTrials.gov)

December 2016

15/10/2016

Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome

Biochemical Response of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Induced by Ursodeoxycholic Acid Only or Combination Therapy of Immunosuppressive Agents

Hepatitis, Autoimmune;Cholangitis;Liver Cirrhosis, Biliary;Cholestasis

Drug: Ursodeoxycholic acid combination of immunosuppressive agents;Drug: Ursodeoxycholic Acid

Xiaoli Fan

NULL

Recruiting

18 Years

75 Years

All

N/A

China